Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Qiagen N.V. Common Shares (NY: QGEN )

39.87 -0.19 (-0.47%)
Official Closing Price Updated: 7:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Qiagen N.V. Common Shares

< Previous 1 2 3 4 5 6 7 Next >
Rising Test Accuracy Standards Needed as On-Site Demand for Covid-19 Testing Increases
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 9, 2021 – USA News Group – After the launch of US President Joe Biden’s pushing of mandatory vaccination/testing in the... 
Via FinancialNewsMedia
Exposures COVID-19
QIAGEN Commits to Reduce Carbon Emissions by Setting Science-Based Target to Reach Net Zero by 2050
From QIAGEN N.V.
Via Business Wire
Qiagen, Becton Dickinson Settle Patent Infringement Lawsuit For $53M
Qiagen N.V. (NYSE: QGEN) settled with Becton Dickinson & Co (NYSE: BDX) a patent infringement lawsuit related to Qiagen's NeuMoDx 96 and NeuMoDx... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
QIAGEN and BD Settle Patent Infringement Lawsuit
From QIAGEN N.V.
Via Business Wire
Qiagen NV (QGEN) Q3 2021 Earnings Call Transcript
QGEN earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Qiagen Clocks 17% Increase In Non-COVID Product Sales; Raises FY21 Guidance
Qiagen N.V.'s (NYSE: QGEN) Q3 revenues grew 11% Y/Y to $535 million (+10% at constant exchange rates), well above the consensus of $434.97 million. Non-COVID... 
Via Benzinga
QIAGEN Reports Strong Results for Third Quarter and First Nine Months Of 2021
From QIAGEN N.V.
Via Business Wire
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics... 
Via Benzinga
Topics Retirement
Exposures Pension
Earnings Scheduled For November 3, 2021
Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.... 
Via Benzinga
QIAGEN expands QIAstat-Dx testing menu with respiratory four-plex panel that differentiates between flu, RSV and SARS-CoV-2
From QIAGEN N.V.
Via Business Wire
QIAGEN Strengthens UK Footprint With Move to New Manchester Facilities
From QIAGEN N.V.
Via Business Wire
QIAGEN N.V. to Release Results for Q3 2021 and First Nine Months of 2021
From QIAGEN N.V.
Via Business Wire
QIAGEN Launches Novel QIAreach QuantiFERON-TB Tuberculosis Test for High-Burden Regions
From QIAGEN N.V.
Via Business Wire
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021
Upgrades According to Roth Capital, the prior rating for Ring Energy Inc (AMEX: 
Via Benzinga
Qiagen Secures DoD Contract To Boost Production Capacity For NeuMoDx
Qiagen NV (NYSE: QGEN) won a U.S. government contract to increase the production capacity for consumables used on its NeuMoDx 96 and 288 integrated PCR testing... 
Via Benzinga
QIAGEN Receives U.S. Department of Defense Contract to Further Expand Production Capacity for NeuMoDx
From QIAGEN N.V.
Via Business Wire
Big Changes Coming to Covid Testing in Response to Rising Demand Under Latest Mandates
Via FinancialNewsMedia
Exposures COVID-19
Why New Covid-19 Test Supplies Will Be Needed Soon in Wake of US President’s New OSHA Mandates
Via FinancialNewsMedia
Exposures COVID-19
QIAGEN to Enter the DAX – Germany’s Leading Stock Market Index
From QIAGEN N.V.
Via Business Wire
QIAGEN Reaches Milestone With Its Kits Used to Process More Than Three Billion Biological Samples to Date
From QIAGEN N.V.
Via Business Wire
QIAGEN and GT Molecular Collaborate to Offer a Complete SARS-CoV-2 Wastewater Detection Solution Based on QIAcuity Digital PCR Technology
From QIAGEN N.V.
Via Business Wire
Qiagen Inks Companion Diagnostic Development, Technology-Licensing Deal With OncXerna
Qiagen NV (NYSE: QGEN) and OncXerna Therapeutics have signed a master agreement to develop a next-generation sequencing (NGS) companion diagnostic for... 
Via Benzinga
QIAGEN and OncXerna Therapeutics Sign Licensing and Master Companion Diagnostic Agreements
From QIAGEN N.V.
Via Business Wire
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
Via Benzinga
Exposures Product Safety
Qiagen's COVID-19 Antigen Test Gets FDA Emergency Use Approval
The FDA has granted emergency use authorization (EUA) to Qiagen N.V.'s (NYSE: QGEN) QIAreach SARS CoV-2 Antigen Test. The rapid, portable test can detect... 
Via Benzinga
Exposures COVID-19 Product Safety
QIAGEN receives U.S. FDA emergency use authorization for rapid portable test that can analyze over 30 samples per hour for SARS-CoV-2 antigen
From QIAGEN N.V.
Via Business Wire
3 Must-Own Healthcare Stocks For Your Portfolio
Healthcare stocks have had a steady run so far this year, with the industry’s growth prospects—based on ongoing digitization to revolutionize and increase demand—motivating investors. Thus, we believe... 
Via Talk Markets
Qiagen Stock Gains As Non COVID Sales Boosts Q2 Topline, Bottom-line
Qiagen N.V. (NYSE: QGEN) reported after the close of the market Thursday that its second-quarter revenues jumped 28% Y/Y as growth in its core product portfolio... 
Via Benzinga
QIAGEN Reports Full Results for Q2 and H1 2021
From QIAGEN N.V.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.